Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer (Q33364017)

26 July 2017

title

Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer (English)

1 reference

26 July 2017

1 reference

Tally Levy

1

1 reference

26 July 2017

Moshe Inbar

2

1 reference

26 July 2017

Joseph Menczer

3

1 reference

26 July 2017

Dan Grisaru

4

1 reference

26 July 2017

Marek Glezerman

5

1 reference

26 July 2017

Tamar Safra

6

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

26 July 2017

1 reference

26 July 2017

volume

95

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

686-690

1 reference

26 July 2017

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.09.005

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1016/J.YGYNO.2004.09.005

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6vjtks4w7zbi5johvhlsjz2sbu

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_6vjtks4w7zbi5johvhlsjz2sbu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6vjtks4w7zbi5johvhlsjz2sbu

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/6vjtks4w7zbi5johvhlsjz2sbu

1 reference

30 July 2022